Background Multiple sclerosis (MS) is a chronic disease that requires lifelong treatment. A
highly effective drug not only for relapsing but also for progressive forms of MS with a …

Background An evolving understanding of the immunopathogenesis of multiple sclerosis
suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a …

Multiple sclerosis (MS) therapy has evolved rapidly with an increased availability of several
immunomodulating therapies over the past two decades. Disease-modifying therapies have …

Multiple sclerosis is a disabling autoimmune disease in which immune cells target central
nervous system (CNS) antigens, leading to demyelination, glial activation, and subsequent …

Ocrelizumab is a recombinant humanized monoclonal antibody selectively targeting CD20-
expressing B cells. The effect of ocrelizumab on primary progressive multiple sclerosis …

Background and Objectives B cell–depleting antibodies were proven as effective strategy for
the treatment of relapsing multiple sclerosis (RMS). The monoclonal antibody ocrelizumab …

Objective: To evaluate the efficacy and safety of ocrelizumab in a Phase III, randomized,
double-blind, placebo-controlled study in primary progressive MS (PPMS). Background: B …

Background We aim to directly compare changes in lymphocyte subpopulations between
chimeric (rituximab) and humanised (ocrelizumab) anti-CD20 antibodies in multiple …

Multiple sclerosis (MS) is a chronic inflammatory, demyelinating, and neurodegenerative
disease affecting the central nervous system, often characterized by the accumulation of …

Background Ocrelizumab, a humanized anti-CD20 monoclonal antibody, has been
approved in Europe for the treatment of adult patients with active relapsing multiple sclerosis …